BACKGROUND/OBJECTIVES: In the last decade, a strict link between epigenetics and metabolism has been demonstrated. Histone deacetylases (HDACs) have emerged as key epigenetic regulators involved in metabolic homeostasis in normal and pathologic conditions. Here we investigated the effect of the class I HDAC inhibitor MS-275 in a model of obesity induced by a high-fat diet (HFD). METHODS: C57BL6/J male mice were fed HFD for 17 weeks and then randomized in two groups, treated intraperitoneally with vehicle dimethylsulfoxide (DMSO) or with the class I selective HDAC inhibitor MS-275 every other day for 22 days. Glucose tolerance test and measurement of body temperature during cold exposure were performed. Adipose tissues and liver were phenotypically characterized through histological analysis. Gene and protein expression analysis of brown and white adipose tissues (WATs) were performed. RESULTS: MS-275 treated mice showed 10% reduction of body weight, lower adipocyte size and improved glucose tolerance. Inhibition of class I HDAC determined reduction of adipocyte size and of fat mass, paralleled by higher expression of adipose functionality markers and by increased rate of lipolysis and fatty acid β-oxidation. MS-275 also promoted thermogenic capacity, related to 'browning' of visceral and subcutaneous WAT, showing increased expression of uncoupling protein 1. In brown adipose tissue, we observed limited effects on gene expression and only reduction of brown adipocyte size. CONCLUSIONS: This study provides evidence that class I HDAC inhibition stimulated functionality and oxidative potential of adipose tissue, improving glucose tolerance and ameliorating the metabolic profile in diet-induced obese mice.
INTRODUCTION
The prevalence of obesity increased at a worrisome rate worldwide and is predicted to continuously grow in the next two decades. The fast increase in the number of obese people is related to a sedentary lifestyle, accompanied by excessive energy intake not adequately counteracted by energy expenditure. 1 Obesity is characterized by excessive accumulation of body fat and it is often associated with insulin resistance and the onset of type 2 diabetes. 2 It is nowadays established that genetic susceptibility has a fundamental role in the development of this disorder, 3 however, a role of epigenetics in the pathophysiology of metabolic disorders has recently emerged. 4 Epigenetic modifications include DNA methylation and histone post-translational modifications, such as acetylation, methylation, ADP-ribosylation and phosphorylation. 5 In the context of metabolic diseases, a number of evidences highlighted the importance of histone acetylation, focusing the attention on the role of histone deacetylases (HDACs). [6] [7] [8] These enzymes, by deacetylating histones compact chromatin making it less accessible to transcriptional activators. 9 Gao et al. 10 demonstrated that sodium butyrate, a short chain fatty acid that inhibits class I and class II HDAC activity, improves diet-induced obesity (DIO) and diabetes. Class II HDACs affect both histone and non-histone proteins and butyrate inhibits both main classes of HDACs thus affecting energy metabolism also via HDAC-independent mechanisms; 11, 12 furthermore it has been shown that butyrate acts through free fatty acid receptors (FFAR2 and FFAR3) on the release of the intestinal factor glucagon-like peptide-1 (Glp1). 13, 14 Therefore, further investigations were undertaken to fully understand the role of HDACs in the regulation of energy metabolism and which class of HDACs is mainly involved in the modulation of metabolic processes. Our previous work demonstrated that in a genetic model of obesity and insulin resistance such as the db/db mouse, the class I selective HDAC inhibitor MS-275 enhanced oxidative metabolism in skeletal muscle and adipose tissue and promoted energy expenditure, leading to reduction of body weight and improvement of insulin sensitivity. 15 Interestingly, MS-275 was able to induce a metabolic switch of white adipose tissue (WAT) toward a more oxidative phenotype resembling the features of brown adipose tissue (BAT), a phenomenon referred to as 'browning'. Upon physiological stimuli such as chronic cold exposure, 16 hormonal stimuli (for example, irisin), 17 pharmacological treatment (thiazolidinediones) 18 or β-adrenergic stimulation, 19 WAT switches the genetic program toward a brown fat-like phenotype characterized by induced expression of uncoupling protein 1 (Ucp1), cell death-inducing DFFA-like effector a (Cidea) and diodinase 2 (Dio2). These inducible or recruitable brown adipocytes, also known as 'brite' (brown in white) or beige adipocytes, compared with classical brown adipocytes show lower number of mitochondria and thermogenesis capacity at basal state; however, upon appropriate external cues, they become multilocular and increase number of mitochondria, resembling BAT phenotype. 20 This morphological change, together with inducible expression of UCP1 and other genes related to mitochondrial biogenesis, results in a cell type that participates to adaptive thermogenesis and energy expenditure similar to classical BAT. It has been shown that browning of WAT is an efficient strategy to counteract obesity and diabetes in rodent models. 21, 22 Genetic obesity and DIO differ in term of lipid metabolism and adipose tissue phenotype. 23 Epidemiological studies showed that dietary habits is an important determinant of body weight in humans and that a diet enriched in fat increases the incidence of obesity. 24 Moreover, leptin resistance in humans is rarely related to a mutation in leptin gene; thus the use of murine models of obesity with dysfunctional leptin signaling (ob/ob or db/db mice) could limit the translational relevance of the studies as it is not completely representative of human pathologic condition. 25 Therefore, a diet-induced model of obesity may provide a framework that mimics more closely overweight humans and may be useful to study the pharmacology of obesity.
In order to evaluate whether biochemical inhibition of class I HDACs could be a promising strategy in the treatment of DIO, here we evaluated the effect of MS-275 in mice fed high-fat diet (HFD). We found that this class I HDAC inhibitor reduced body weight and improved glucose tolerance. Interestingly, treatment with MS-275 increased thermogenic capacity and induced browning of both visceral and subcutaneous WAT. Our work demonstrated the crucial importance of class I HDACs in the pathophysiology of obesity, unraveling the role of these enzymes in the determination of metabolic signature of WAT.
MATERIALS AND METHODS

Animal studies
For HFD feeding experiment, C57BL/6J male mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). Six-week-old male mice were fed HFD (60% calories from fat, D12492, Research Diet, New Brunswick, NJ, USA) for 17 weeks, monitoring body weight and fasting glycemia. At week 18, mice were randomized and treated for 22 days every other day with intraperitoneal injection of vehicle (dimethylsulfoxide (DMSO)) or MS-275 (10 mg kg -1 ). At the end of treatments, brown and WATs (inguinal subcutaneous and mesenteric visceral fat pads), liver and blood samples were collected from individual animals. For blood analysis, HFD fed mice were fasted for 16 h and blood was collected from the tail vein. Glucose levels were determined using One touch Ultra glucometer (LifeScan Italy, Milano, Italia). Triglyceride and cholesterol levels were determined by Plasma Triglyceride Kit (Sentinel, Diagnostics, Milan, Italy) and by Plasma Cholesterol Kit (Sentinel). Non-esterified fatty acids (NEFA) levels were determined by NEFA Kit (Wako Diagnostics, Mountain View, CA, USA). Insulin levels were determined using AlphaLISA Human Insulin Research Immunoassay Kit (Perkin Elmer, Waltham, MA, USA). Adiponectin and leptin levels were determined using ELISA assay Kits (Genway, San Diego, CA, USA). For glucose and insulin tolerance test, mice were fasted for 16 h, and glucose levels from tail vein blood were determined before and 30, 60, 90 and 120 min after intraperitoneal injection of glucose (2 g kg -1 ). For cold challenge test, basal rectal temperature was measured at 24°C. Subsequently, mice were housed for 140 min at 4°C and rectal temperature was measured every 20 min.
All experiments were conducted in accordance with Italian regulations (decree no. 116, 27 January 1992).
Histological analysis of adipose tissues BAT, subcutaneous WAT and liver were fixed with Carnoy solution (six parts 100% ethanol, three parts chloroform and one part glacial acetic acid) for 24 h at 4°C. Tissues were then transferred to 100% ethanol. Tissues were embedded in paraffin and 8 μm sections were stained with hematoxylin and eosin. Images were taken at × 20 magnification. Cell size of adipocytes from WAT sections were quantitated using Photoshop CS6 (Adobe Systems Inc., San Jose, CA, USA).
Gene expression
RNA from adipose tissues was isolated using Qiazol Reagent (Qiagen, Hilden, Germany), purified with commercial kit (RNeasy Lipid Tissue Mini kit, Qiagen) and quantitated with Nanodrop (Thermo Scientific, Wilmington, DE, USA). Specific mRNA was amplified and quantitated by real-time quantitative PCR, using iScriptTM One Step RT PCR for Probes (Bio-Rad Laboratories, Berkeley, CA, USA), following the manufacturer's instructions. Data were normalized to 36B4 mRNA and quantitated setting up a standard curve.
Each sample was run in triplicate using 36B4 as reference gene. Primers and probes were obtained from Eurofins MWG Operon (Eurofins genomics, Ebersberg, Germany) and are available on request.
Protein analysis
Adipose tissues were lysed with 2X sodium dodecyl sulfate sample buffer (20% glycerol, 4% sodium dodecyl sulfate, 100 mM Tris-HCl pH 6.8, 100 mM dithiothreitol, 0.002% bromophenol blue), 1 mM protease inhibitors (Sigma-Aldrich, St Louis, MO, USA), and homogenized with TissueLyser (Qiagen). Tissue lysates were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred onto nitrocellulose membranes and sample loading and transfer were evaluated by Ponceau staining. Membranes were then blocked in 5% non-fat dry milk in 1X Trisbuffered saline. The following primary antibodies were used: peroxisome proliferator-activated receptor γ (PPARγ; 1:500, sc-7273, Santa Cruz, Biotechnology, Dallas, TX, USA), UCP1 (1:1000, ab10983, Abcam, Cambridge, UK). Horseradish peroxidase-conjugated goat anti-mouse (SigmaAldrich) and goat anti-rabbit (Cell Signaling, Danvers, MA, USA) secondary antibodies were used for detection with chemiluminescence (ECL, Pierce, Thermofisher Scientific, Waltham, MA, USA).
Immunohistochemistry
Sections of WAT and BAT (8 μm) were deparaffinized and antigen retrieval was performed with 0.05 M NH 4 Cl for 30 min at room temperature. Endogenous peroxidase activity was blocked with 1% H 2 O 2 for 20 min. Blocking was performed in 1% bovine serum albumin-0.1% Triton X-100 for 1 h. Anti-UCP1 (Abcam) was applied (1:300) overnight at 4°C, followed by incubation with biotinylated secondary antibodies (1:3000). Histochemical reactions were performed using diaminobenzidine. Quantification of histochemical analysis was performed counting the number of pixels in gray-scale intervals, using the software ImageJ (National Institutes of Health, Bethesda, MD, USA). Color channels were split and the analysis was performed on green channel. The software generates the list of gray-scale intervals (0-255) and the number of pixels in each interval.
Magnetic resonance imaging
At day 18 of treatment, mice were anesthetized and analyzed in a 4.7 Tesla Avance II magnetic resonance imaging (MRI) scanner (Bruker Corporation, Billerica, MA, USA). After a gradient-echo scout, 16 axial 1-mm-thick T1-weighted slices were placed in the abdominal region spanning from kidneys to bladder inclusive. The field of view was 30 × 30 mm 2 with a matrix of 128 × 128 pixels. Four averages of a spin echo sequence with echo time to 10 ms and repetition time 400 ms were acquired in 3'25". The slice immediately frontal with respect to the ilium bone was chosen for visceral fat estimation and was computed as follows: (fat area)/(slice area). Areas were measured with Photoshop (Adobe Systems).
Mass spectrometry analysis of hepatic fatty acids
Livers from HFD fed obese mice treated with vehicle or with MS-275 were homogenized in methanol with TissueLyser (Qiagen). For quantitative analysis of fatty acids, aliquots of methanolic extracts after addition of internal standards (heneicosanoic acid, C21:0, and 13 C-labeled linoleic acid, Sigma-Aldrich) were subjected to acid hydrolysis and processed as previously described. 26 Fatty acid quantification was performed on an API-4000 triple quadrupole mass spectrometer (AB SCIEX, Framingham, MA, USA) coupled with a HPLC system (Agilent, Santa Clara, CA, USA) and CTC PAL HTS autosampler (PAL System, CTC Analytics AG, Zwingen, Switzerland).
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Human adipose stromal cells
Cells were plated at a density of 10 5 cells ml -1 and differentiated for 4 days in presence of 50 μM insulin, 100 nM dexamethasone, 0.25 mM isobutylmethylxantine (Sigma-Aldrich) and 100 nM rosiglitazone (Cayman Chemical, Ann Arbor, Michigan, MI, USA). Then medium was refreshed every other day from day 4 to day 10 of differentiation with of 50 μM insulin, 100 nM dexamethasone (Sigma-Aldrich) and 100 nM rosiglitazone (Cayman Chemical). At the end of differentiation, cells were treated for 48 h with DMSO or with 1 μM MS-275.
Statistical analyses
Statistical analyses were performed using the unpaired two-tailed Student's t-test with GraphPad PRISM (San Diego, CA, USA).
RESULTS
Inhibition of class I HDACs improves obese phenotype and reduces adiposity
To investigate whether inhibition of class I HDACs could counteract obesity and insulin resistance in a mouse model of DIO (DIO mice), we fed 6-week-old male C57BL/6J mice with HFD (60% kcal from fat). After 17 weeks on HFD, mice were randomized in two groups, without statistically significant difference in weight and fasting glycemia. Mice were treated for 22 days, every other day, with vehicle DMSO or with the class I selective HDAC inhibitor MS-275 10 mg kg -1 ( Figure 1a ), as previously reported. 15 Starting from day 16 of treatment, MS-275-treated mice showed a lower body weight (Figure 1b ), yielding 10% reduction at day 22, with no statistically significant change in daily food intake (Supplementary Figure 1A) . Body weight of each mouse before and after the treatments was reported in Table 1 . MS-275 decreased the percentage of total WAT (Figure 1c, Supplementary Figure 1E ) and in particular MRI analysis showed statistical significant reduction of subcutaneous WAT (Supplementary Figure 1B) and a mild but not statistically significant decrease of visceral WAT (Supplementary Figure 1C) . No difference of BAT mass was detected in mice treated with MS-275 (Supplementary Figure 1D) . Glucose tolerance test showed that treatment with MS-275 improved glucose clearance in diet-induced obese mice (Figure 1d ), whereas insulin tolerance test showed no differences between the two groups (Supplementary Figure 1J) . MS-275 was also able to improve leptin resistance as assessed by reduced levels of circulating leptin and by the increased expression of hypothalamic leptin receptor (Supplementary Figures 1F and 1G ), whereas it had no effect on circulating levels of insulin and adiponectin (Supplementary Figure 1H and 1I ). Hematoxylin and eosin staining of subcutaneous (inguinal) and visceral (mesenteric) WAT revealed that adipocytes were smaller in MS-275-treated mice (Figure 1e ).
MS-275 increased expression of markers of lipid catabolism and adipose functionality
To explain the phenotypic effects observed in MS-275-treated mice, we analyzed the gene expression profile in their adipose tissue depots. Interestingly, we found that MS-275 increased expression of the master regulator of adipogenesis Pparg and of other typical markers of adipose tissue functionality (Fabp4, Adipoq, Glut4 and Plin) (Figures 2a and b) . The augmented expression of most of these genes (except Glut4) was statistically significant in the visceral WAT, whereas, in spite of the general trend, only Glut4 and Plin resulted significantly enhanced subcutaneous WAT. Of note, western blot analysis of subcutaneous WAT revealed strong increase in PPARγ protein expression (Figure 2c, Supplementary Figure 1K) , suggesting a posttranscriptional modulation of this protein in response to class I HDAC inhibition. We also found that class I HDAC inhibitor increased the expression of genes involved in lipolysis (Atgl) and fatty acid β-oxidation (Cpt1b, Acadl) in both subcutaneous ( Figure 2d ) and visceral (Figure 2e ) WAT. We hypothesized that the reduced lipid content in white adipocytes is the result of a higher catabolism, and that it is not related to an inefficient storage of lipids in WAT. In line with this observation, we did not detect an increase in circulating levels of triglycerides (Supplementary Figure 2A) and cholesterol (Supplementary Figure 2B) . Measurement of NEFA revealed mild, although not statistically significant, increase in MS-275 group (Figure 2f) . Moreover, we did not observe differences in the level of fatty acids in the liver of MS-275 treated mice, as detected by hematoxylin and eosin staining (Supplementary Figure 2C) and by mass spectrometry analysis (Supplementary Figure 2D) , indicating that there is no ectopic lipid deposition in the liver in response to the HDAC inhibitor. To rule out the contribution of skeletal muscle to the metabolic profile in MS-275-treated mice, we analyzed expression of genes regulating metabolism in gastrocnemius (Supplementary Figure 2E) and found no changes in the expression of Ppargc1a, Pppargc1b and of cytochrome C (CytC). On the other hand, we detected increased expression of mitochondrial biogenesis genes Tfam and Tfb1m (Supplementary Figure 2E) . Interestingly, gene encoding for the electron transport chain protein COX7A1 was significantly reduced, suggesting no increase in oxidative potential upon MS-275 treatment in skeletal muscle. Moreover, we found reduced expression of Glut4, indicating that amelioration of systemic glucose tolerance is not related to improved glucose uptake in skeletal muscle.
Inhibition of class I HDACs increases thermogenic capacity
Previous results in db/db mice demonstrated that class I HDAC inhibition increased heat production. 15 Thus, we investigated whether treatment with MS-275 could affect thermogenic capacity in diet-induced obese mice. After acute exposure to 4°C, MS-275-treated mice were able to better cope the cold challenge (Figure 3a) . The organ most involved in the regulation of body temperature via non-shivering thermogenesis is BAT. 27 MRI of interscapular area revealed that BAT mass was not affected by MS-275 treatment (Supplementary Figure 1D) . Hematoxylin and eosin staining in BAT from control and MS-275-treated mice showed that the HDAC inhibitor altered tissue morphology (Figure 3b , top panels), apparently reducing lipid accumulation, typically increased in BAT from obese mice. However, immunohistochemical analysis of UCP1 showed no differences in vehicle and MS-275-treated mice (Figure 3b, bottom panels) . Accordingly, gene expression analysis did not show changes in the mRNA and protein expression of the key regulator of thermogenesis UCP1 (Figures 3c and d) and of the other genes typically expressed in brown fat (Adrb3, Cidea and Prdm16) (Figure 3c ). Interestingly, we detected an increased expression of typical BAT markers Dio2 and Elovl3.
Inhibition of class I HDACs promotes lipid oxidation and browning in white fat As we found increased heat production during cold exposure but we did not observe higher expression of UCP1 in BAT of mice treated with the class I HDAC inhibitor, we wanted to explore whether MS-275 was able to induce a brown-like phenotype in WAT also in a model of DIO. Interestingly, mice treated with HDAC inhibitor showed clear signs of browning of both subcutaneous (Figure 4a ) and visceral WAT (Figure 4b ), as Ucp1 and other genes typically expressed in BAT (Adrb3, Cidea, Dio2 and Ppara) were upregulated. Immunohistochemical analysis of UCP1 confirmed its higher expression in subcutaneous (Figure 4c ) and visceral fat (Figure 4d ) of MS-275-treated mice. To deeply investigate the phenotypical rearrangement occurring upon class I HDAC inhibition in WATs, we performed further gene expression analysis and we found upregulation of markers of fatty acid synthesis: fatty acid synthase (Fasn) was increased in both subcutaneous WAT and visceral WAT, whereas acetyl CoA carboxylase (Acaca) was significantly upregulated in visceral WAT (Supplementary Figures  3A and 3B) . Moreover, the gene expression analysis of inflammation markers revealed no differences in the mRNA of M1 markers iNOS and IL1β in adipose tissues (Supplementary Figures 3C and   3D ), and a significant increase in subcutaneous WAT of markers of alternatively activated macrophages (M2) markers MRC1 and Cd163. We also measured levels of apoptosis markers (caspases) but found no changes in MS-275-treated mice (Supplementary Figures 3E and 3F) , thus ruling out the contribution of apoptosis in white fat in body weight reduction. To extend our observations in murine models to the human settings, we treated differentiated human adipose stromal cells with vehicle (DMSO) or with MS-275 for 48 h: we detected increased rate of differentiation in presence of class I HDAC inhibitor as assessed by Oil Red O staining (Supplementary Figures 3G and 3H ). Although this preliminary observation suggests a possible role of class I HDACs in human adipose tissue physiology, further investigations will be required to assess whether modulation of class I HDACs activity may reprogram adipocyte metabolism in humans.
DISCUSSION
Human obesity is often related to a diet enriched in fat and carbohydrates in Western countries. 24 To provide new knowledge about metabolic disorders consequent to an unhealthy intake of calories from fat, the most useful murine model is a diet-induced model of obesity. It has in fact been shown that the use of genetic models of obesity with dysfunctional leptin signaling (ob/ob or db/ db mice) could not be completely representative of human pathologic condition, considering that genetic mutations of leptin gene are rare in obese patients. Previous investigations showed that treatment of diet-induced obese mice with HDAC inhibitor sodium butyrate improved insulin sensitivity by promoting energy metabolism in skeletal muscle and BAT. 10 However, the short chain fatty acid butyrate may display effects also through non-HDAC targets (for example, FFAR2 and FFAR3). 13, 14 Therefore, in this study we decided to adopt a murine model of DIO to investigate the role of HDACs in this pathological condition, using the synthetic class I HDAC selective inhibitor MS-275. Here we reported that inhibition of class I HDACs by MS-275 reduces body weight and enhances glucose tolerance. The fact that treatment with MS-275 improved glucose tolerance test but did not affect insulin tolerance test could be ascribed to higher expression of Glut4 in adipose tissues resulting in amelioration of the capacity to handle glucose loads, rather than to increased insulin signaling and sensitivity. Moreover, class I HDAC inhibitor increased thermogenic capacity. This result prompted us to investigate further the effects of class I HDAC inhibitor in BAT. Although BAT mass did not change, we found that BAT morphology was improved in MS-275-treated mice, which showed higher number of small multilocular brown adipocytes, expressing BAT markers such as Dio2 and Elovl3. Interestingly, no significant changes were found in the expression of Ucp1 and Adrb3 thus arguing against increased heat production by BAT following MS-275 treatment. The two proteins encoded by these genes, uncoupling protein 1 and β 3 adrenergic receptor, are in fact considered the key activators of the thermogenic program. However, we cannot completely exclude the contribution of BAT to increased thermogenesis in MS-275-treated mice because an important contribution of DIO2 to thermogenesis has been reported:
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Dio2 − / − mice during cold exposure become hypothermic, despite normal expression of UCP1, demonstrating that type 2 iodothyronine deiodinase and uncoupling protein 1 regulate thermogenesis in a concerted manner. Thus, we do not rule out that long-term exposure of MS-275-treated mice to cold could result in an increase of BAT uncoupling and functionality. However, an explanation for the increased thermogenic activation in response to acute cold exposure in MS-275-treated mice came from the analysis of white fat. Our results indicate, in fact, that MS-275-elicited browning of WAT contributes in counteracting DIO. As previously reported, browning of WAT occurring without changes of uncoupling protein 1 in BAT is a successful strategy to counteract obesity. 17, 29, 30 Interestingly, in both subcutaneous and visceral WAT from MS-275-treated mice, we observed upregulation of Ucp1 and other markers of BAT. Thus 'browning' of WAT consequent to inhibition of class I HDACs in DIO mice occurred both in subcutaneous and visceral WAT. Accordingly, expression of WAT functionality markers and of genes involved in triglycerides and fatty acid catabolism were upregulated in both types of white fat, although to a greater extent in visceral WAT. To date, browning of WAT has been obtained by pharmacological treatment or by genetic manipulation 18, 20, 31 in inguinal WAT or in epidydimal WAT. Our data, showing browning in visceral mesenteric WAT, suggest that class I HDAC selective inhibition induces deep reprogramming of adipose phenotype, resulting in more functional visceral adipocytes. Recently, it has been demonstrated that leptin mediates WAT browning through sympathetic nerve activity on adipose tissue through proopiomelanocortin neurons. 32 Interestingly, leptin levels were reduced in MS-275-treated mice, thus we hypothesize that these mice are more sensitive to leptin. Gene expression analysis in hypothalamus seems to corroborate this interpretation, as leptin receptor mRNA levels were higher in mice treated with the HDAC inhibitor MS-275. Based on our results (higher expression of leptin receptor leading to increased leptin sensitivity in hypothalamus in mice treated with MS-275) and on the published literature, it is possible that leptin has a role in MS-275-mediated browning of WAT. Gene expression analysis indicates that white adipocytes of MS-275-treated mice could catabolize triglycerides at higher rate as indicated by increased expression of adipose tissue lipase (Atgl). Typically, high lipolytic rate correlates with increased level of plasma NEFA, however, in our experimental settings circulating NEFA are not statistically different in two groups of mice. In MS-275-treated mice, this is probably the result of enhanced fatty acid β-oxidation within WAT depots, which use fatty acids as a metabolic fuel, as proved by increased expression of β-oxidation genes (that is, Ppara, Acadl and Cpt1b). Similarly to what happens to BAT during cold exposure 33 and to WAT upon β 3 -adrenergic stimulation, 34 MS-275 also boosted de novo fatty acid synthesis in subWAT and viscWAT, further confirming the browning effect mediated by class I HDAC inhibitor. We infer that activation of lipogenic program in brown-like WAT may be an adaptive response to the increased requirement of fuel molecules to feed the accelerated electron transport chain (ETC) flux because of uncoupling of ETC from oxidative phosphorylation. The finding of improved functionality of mesenteric WAT is particularly relevant when considering the link between the intra-abdominal fat accumulation typical of obesity and other related severe complications, such as insulin resistance/type 2 diabetes and ultimately cardiovascular events. In spite of these considerations, the MRI analysis revealed a significant reduction of adipose mass in subcutaneous WAT, whereas in visceral WAT the trend did not reach statistical significance. This could depend on different features of viscWAT and subWAT: subcutaneous fat, which is less susceptible to inflammation, 35 is characterized by larger adipocytes and higher plasticity as compared with visceral fat. MS-275 reduced the size of both subcutaneous and visceral adipocytes, however, the effect was more pronounced in subWAT. This marked reduction of subcutaneous adipocytes hypertrophy can explain the reduced subWAT mass, as detected by MRI analysis. Conversely, gene expression analysis of functionality markers showed that MS-275 is more efficient in visceral fat: visceral adipocytes are smaller than subcutaneous adipocytes, yet visceral fat is more susceptible to inflammation because of the lower critical size adipocytes in this depot. 35 Thus, although the reduction in adipocyte size is not as evident as in subWAT, the decrease of adipocyte hypertrophy is sufficient to rescue adipocyte functionality, as assessed by gene expression analysis. Student's t-test, *P o0.05, **P o0.01, ***P o0.001.
On the contrary, subcutaneous adipocytes in obesity feature greater expandability that does not impair their functionality. For this reason, the effects of MS-275 on the expression of functionality markers are less pronounced in subWAT as compared with the effects observed in viscWAT. In both subcutaneous and visceral WAT, MS-275 has no effect on adipose tissue inflammation typically associated to obesity, as assessed by unaltered expression of pro-inflammatory macrophage (M1) markers. However, in subWAT inhibition of class I HDAC is able to induce the expression of alternatively activated macrophages (M2). The increased expression of these markers further corroborates the browning phenotype, as it has been reported that M2 macrophages produce cathecolamines that sustain adaptive thermogenesis activation, 36 driving the development of coldinduced beige fat in inguinal WAT. 37 Furthermore, the unchanged expression level of caspases in subWAT and viscWAT highlights that inhibition of class I HDAC does not promote adipocytes apoptosis.
Assuming that HDAC inhibitors do not act on specific organs but exert ubiquitous effects, we cannot exclude that MS-275 affects metabolism and physiology of other organs. At this regard, we looked at skeletal muscle gene expression and found that in gastrocnemius treatment with MS-275 slightly increased the expression of mitochondrial biogenesis genes (Tfam, Tfb1m) but it decreased expression of insulin-dependent glucose transporter Glut4. This result may indicate that amelioration of systemic glucose tolerance is probably not related to improved glucose utilization in skeletal muscle, but to ameliorated glucose clearance by adipose tissue. It should be noted that selective Glut4 overexpression in adipose tissue prevents glucose intolerance in mice fed HFD; 38 consistently, in our experimental model MS-275 increased Glut4 expression in subcutaneous WAT, which is likely to contribute to improved glucose tolerance.
Another organ that may contribute to glucose tolerance is liver. However, histological images and mass spectrometry analysis did not show significant difference in hepatic lipid levels between control and MS-275 treated mice. Therefore, we tend to exclude that the liver may have a role in improving glucose clearance in our experimental model.
It has been reported that hepatic deletion of HDAC3 39, 40 leads to lipid accumulation in the liver. However, although MS-275 targets both HDAC1 and HDAC3, we found no hepatic steatosis in the liver of DIO mice treated with this inhibitor. This difference may be ascribed to the effect of global versus local HDAC3 inhibition: in obese and diabetic mice, systemic HDAC3 inhibition (that is, MS-275 treatment) increases oxidative metabolism and energy expenditure in other tissues such as adipose tissue, thus preventing hepatic lipid buildup.
The preliminary observations in human differentiated adipocytes highlight the role of class I HDACs in the regulation of adipocyte differentiation and functions in the human settings. Further analyses will shed light whether these effects result in a metabolic switch of human white adipocytes and whether HDAC inhibition could be evaluated as a possible strategy in the treatment of metabolic disorders.
In conclusion, our results show that inhibition of class I HDACs ameliorates obese and diabetic phenotype in a model of DIO. This is a consequence of improved functionality of adipose tissue, preventing the excessive lipid accumulation that would impair adipocyte function and lead to insulin resistance. The role of class I HDACs in adipose tissue pathophysiology could be further explored in the quest of new therapeutic avenues for obesity and type 2 diabetes.
